News & Updates

In the treatment of polycystic ovary syndrome (PCOS), the combination of metformin plus oral contraceptives appears to benefit women without obesity, inducing favourable effects on glucose metabolism with no further harm on lipid metabolism, according to the results of a meta-analysis.

Combination therapy using yttrium 90 (Y90) radioembolization and sorafenib/nivolumab for patients with hepatocellular carcinoma (HCC), with hepatic vein (HV) or inferior vena cava (IVC) invasion, results in better outcomes, as indicated by increased response rates, overall survival (OS), and progression-free survival (PFS) benefits, a study has found.

Treatment with mesalamine may only have modest efficacy for the global symptoms of irritable bowel syndrome (IBS), specifically IBS that causes increased diarrhoea, according to the results of a meta-analysis. However, the quality of evidence appears to be low.

Carnitine appears to be beneficial in the treatment of women with polycystic ovary syndrome (PCOS), with the drug helping improve ovulation, clinical pregnancy, insulin resistance, and body mass index, according to the results of a meta-analysis.

Vaccines are safe and effective in patients with autoimmune inflammatory rheumatic disease (AIIRD), according to several physicians who participated in a recent international survey. However, many of the respondents are also responsible for not encouraging their patients to get vaccinated.

Sodium-glucose cotransporter-2 inhibitors (SGLT-2Is) confer the greatest reduction in kidney and cardiovascular risks in patients with type 2 diabetes mellitus (T2DM) and chronic kidney disease (CKD), according to a study.

The use of pembrolizumab in the neoadjuvant setting appears to be associated with a higher rate of downstaging and a survival advantage among patients with muscle-invasive bladder cancer (MIBC) who are ineligible for cisplatin-based neoadjuvant chemotherapy, according to a study presented at this year’s ASCO Genitourinary Cancers Symposium.

First-line treatment of advanced renal cell carcinoma (aRCC) with nivolumab plus cabozantinib (N+C) results in sustained survival and response benefits at 3 years minimum follow-up, which is consistent with previous follow-ups, according to a study presented at the 2023 ASCO GU Cancers Symposium.